Scan to Download ios&Android APP

Trade Instil Bio, Inc. - TIL CFD

4.57
3.99%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading Conditions
Long position overnight fee -0.0225%
Short position overnight fee -0.0219%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 4.76
Open* 4.52
Day's Range* 4.46 - 4.46
1-Year Change* -0.88%
Volume N/A
Average Vol. (3m) 12.2577
52 wk Range N/A
Market Cap 896.188
P/E Ratio N/A
Shares Outstanding 129694000
Revenue N/A
EPS -1.63741
Dividend (Yield %) N/A
Beta N/A
Next Earnings Date Nov 14, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jun 29, 2022 4.57 -0.01 -0.22% 4.58 4.67 4.46
Jun 28, 2022 4.76 0.13 2.81% 4.63 4.88 4.62
Jun 27, 2022 4.79 -0.39 -7.53% 5.18 5.18 4.77
Jun 24, 2022 5.07 -0.05 -0.98% 5.12 5.40 4.98
Jun 23, 2022 5.25 0.44 9.15% 4.81 5.26 4.71
Jun 22, 2022 4.80 0.10 2.13% 4.70 5.00 4.62
Jun 21, 2022 4.67 -0.19 -3.91% 4.86 5.02 4.64
Jun 17, 2022 4.64 0.57 14.00% 4.07 4.78 4.06
Jun 16, 2022 4.18 -0.61 -12.73% 4.79 4.81 3.88
Jun 15, 2022 4.94 0.15 3.13% 4.79 5.12 4.79
Jun 14, 2022 4.85 0.03 0.62% 4.82 5.14 4.73
Jun 13, 2022 4.88 -0.27 -5.24% 5.15 5.22 4.88
Jun 10, 2022 5.46 -0.05 -0.91% 5.51 5.53 5.28
Jun 9, 2022 5.72 -0.25 -4.19% 5.97 6.08 5.69
Jun 8, 2022 6.16 0.28 4.76% 5.88 6.57 5.88
Jun 7, 2022 6.13 0.50 8.88% 5.63 6.14 5.57
Jun 6, 2022 5.92 -0.08 -1.33% 6.00 6.11 5.81
Jun 3, 2022 5.97 0.27 4.74% 5.70 6.21 5.70
Jun 2, 2022 5.85 0.15 2.63% 5.70 5.92 5.70
Jun 1, 2022 5.81 -0.17 -2.84% 5.98 6.04 5.61

Instil Bio, Inc. Events

Time (UTC) Country Event
Monday, November 14, 2022
12:00
  US
Q3 2022 Instil Bio Inc Earnings Release
View all events
  • Annual
  • Quarterly
2019 2020 2021
Total revenue 0 0.138 0
Revenue 0 0.138 0
Total Operating Expense 6.585 33.782 155.56
Selling/General/Admin. Expenses, Total 2.558 14.383 48.309
Research & Development 4.027 19.399 107.251
Operating Income -6.585 -33.644 -155.56
Interest Income (Expense), Net Non-Operating 0.068 -3.687 -1.195
Other, Net -0.005 -0.256
Net Income Before Taxes -6.522 -37.587 -156.755
Net Income After Taxes -6.522 -37.738 -156.794
Net Income Before Extra. Items -6.522 -37.738 -156.794
Net Income -6.522 -37.738 -156.794
Income Available to Common Excl. Extra. Items -6.522 -37.738 -156.794
Income Available to Common Incl. Extra. Items -6.522 -37.738 -156.794
Diluted Net Income -6.522 -37.738 -156.794
Diluted Weighted Average Shares 125.812 125.812 105.993
Diluted EPS Excluding Extraordinary Items -0.05184 -0.29995 -1.47928
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.05184 -0.29995 -1.47928
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total revenue 0 0 0 0 0
Revenue 0 0 0 0 0
Total Operating Expense 23.403 35.381 43.024 53.752 54.286
Selling/General/Admin. Expenses, Total 8.979 14.195 13.96 11.175 15.112
Research & Development 14.424 21.186 29.064 42.577 39.174
Operating Income -23.403 -35.381 -43.024 -53.752 -54.286
Interest Income (Expense), Net Non-Operating 0.071 -0.089 -0.639 -0.538
Net Income Before Taxes -23.332 -35.47 -43.663 -54.29 -54.605
Net Income After Taxes -23.128 -35.311 -43.005 -55.35 -54.117
Net Income Before Extra. Items -23.128 -35.311 -43.005 -55.35 -54.117
Net Income -23.128 -35.311 -43.005 -55.35 -54.117
Income Available to Common Excl. Extra. Items -23.128 -35.311 -43.005 -55.35 -54.117
Income Available to Common Incl. Extra. Items -23.128 -35.311 -43.005 -55.35 -54.117
Diluted Net Income -23.128 -35.311 -43.005 -55.35 -54.117
Diluted Weighted Average Shares 128.743 128.743 128.794 129.205 129.119
Diluted EPS Excluding Extraordinary Items -0.17964 -0.27427 -0.3339 -0.42839 -0.41912
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.17964 -0.27427 -0.3339 -0.42839 -0.41912
Other, Net -0.319
  • Annual
  • Quarterly
2019 2020 2021
Total Current Assets 9.286 246.138 464.02
Cash and Short Term Investments 8.895 241.714 454.099
Cash & Equivalents 8.895 241.714 37.59
Total Receivables, Net 0 3.173
Prepaid Expenses 0.334 1.181 9.921
Other Current Assets, Total 0.057 0.07
Total Assets 9.476 319.012 609.983
Property/Plant/Equipment, Total - Net 0.19 55.341 121.999
Property/Plant/Equipment, Total - Gross 0.21 55.647 124.978
Accumulated Depreciation, Total -0.02 -0.306 -2.979
Goodwill, Net 0 5.722 5.722
Intangibles, Net 0 10.104 10.104
Other Long Term Assets, Total 0 1.707 8.138
Total Current Liabilities 1.42 13.281 41.358
Accounts Payable 0.979 3.495 5.568
Accrued Expenses 0.441 8.121 33.539
Notes Payable/Short Term Debt 0 0 0
Other Current Liabilities, Total 0 1.665 2.251
Total Liabilities 1.42 26.645 54.7839
Total Long Term Debt 0 0 0
Deferred Income Tax 0 2.471 2.426
Other Liabilities, Total 0 10.893 10.9999
Total Equity 8.056 292.367 555.199
Redeemable Preferred Stock 14.948 331.966 0
Common Stock 0 0 0.00013
Additional Paid-In Capital 0.293 5.607 757.003
Retained Earnings (Accumulated Deficit) -7.185 -44.923 -201.717
Other Equity, Total 0 -0.283 -0.087
Total Liabilities & Shareholders’ Equity 9.476 319.012 609.983
Total Common Shares Outstanding 125.812 125.812 129.028
Short Term Investments 416.509
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 613.759 574.461 523.087 464.02 390.701
Cash and Short Term Investments 609.639 566.725 515.358 454.099 379.52
Cash & Equivalents 609.639 566.725 20.4 37.59 61.473
Total Receivables, Net 2.058 3.16 3.644
Prepaid Expenses 1.992 4.576 4.085 9.921 11.181
Other Current Assets, Total 0.07 0 0
Total Assets 696.142 672.67 647.397 609.983 564.936
Property/Plant/Equipment, Total - Net 62.859 78.576 103.69 121.999 155.328
Property/Plant/Equipment, Total - Gross 63.567 79.924 105.777 124.978 159.062
Accumulated Depreciation, Total -0.708 -1.348 -2.087 -2.979 -3.734
Goodwill, Net 5.722 5.722 5.722 5.722 5.722
Intangibles, Net 10.104 10.104 10.104 10.104 10.104
Other Long Term Assets, Total 3.698 3.807 4.794 8.138 3.081
Total Current Liabilities 17.325 23.844 32.087 41.358 36.777
Accounts Payable 3.729 5.225 5.254 5.568 7.711
Accrued Expenses 12.018 16.096 24.634 33.539 27.556
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1.578 2.523 2.199 2.251 1.51
Total Liabilities 30.989 37.1979 45.9769 54.7839 56.377
Total Long Term Debt 0 0 0 0 0
Deferred Income Tax 2.267 2.11 1.475 2.426 1.946
Other Liabilities, Total 11.397 11.2439 12.4149 10.9999 17.654
Total Equity 665.153 635.472 601.42 555.199 508.559
Redeemable Preferred Stock 0 0 0 0
Common Stock 0 0.00013 0.00013 0.00013 0.00013
Additional Paid-In Capital 733.457 739.044 747.891 757.003 764.834
Retained Earnings (Accumulated Deficit) -68.051 -103.362 -146.367 -201.717 -255.834
Other Equity, Total -0.253 -0.21 -0.104 -0.087 -0.44113
Total Liabilities & Shareholders’ Equity 696.142 672.67 647.397 609.983 564.936
Total Common Shares Outstanding 128.743 128.743 128.857 129.028 129.218
Short Term Investments 494.958 416.509 318.047
  • Annual
  • Quarterly
2019 2020 2021
Net income/Starting Line -6.522 -37.738 -156.794
Cash From Operating Activities -5.293 -29.616 -122.138
Cash From Operating Activities 0.02 0.256 2.752
Non-Cash Items 0.843 6.391 27.543
Changes in Working Capital 0.366 1.475 4.361
Cash From Investing Activities -0.76 -51.122 -474.396
Capital Expenditures -0.21 -50.816 -57.831
Other Investing Cash Flow Items, Total -0.55 -0.306 -416.565
Cash From Financing Activities 14.948 313.048 393.164
Financing Cash Flow Items 0 0.065 -0.069
Issuance (Retirement) of Stock, Net 14.948 312.983 393.233
Foreign Exchange Effects 0 0.559 -0.304
Net Change in Cash 8.895 232.869 -203.674
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -23.128 -58.439 -101.444 -156.794 -54.117
Cash From Operating Activities -17.729 -49.953 -79.348 -122.138 -55.051
Cash From Operating Activities 0.439 1.095 1.859 2.752 0.899
Non-Cash Items 3.008 8.565 18.037 27.543 7.866
Changes in Working Capital 1.952 -1.174 2.2 4.361 -9.699
Cash From Investing Activities -9.129 -17.622 -534.354 -474.396 77.867
Capital Expenditures -9.129 -17.622 -39.367 -57.831 -20.235
Other Investing Cash Flow Items, Total 0 0 -494.987 -416.565 98.102
Cash From Financing Activities 394.705 392.845 392.966 393.164 0.338
Financing Cash Flow Items -0.069 -0.069 -0.069 -0.069 0
Issuance (Retirement) of Stock, Net 394.774 392.914 393.035 393.233 0.338
Foreign Exchange Effects 0.078 -0.259 -0.128 -0.304 0.729
Net Change in Cash 367.925 325.011 -220.864 -203.674 23.883

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
427000+

Traders

71000+

Active clients monthly

$46000000+

Monthly investing volume

$17000000+

Withdrawn each month

Instil Bio, Inc. Company profile

About Instil Bio Inc

Instil Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a cell therapy pipeline of autologous tumor-infiltrating lymphocyte (TIL) therapies for the treatment of patients with cancer. TIL therapies leverage platform for TIL manufacturing has been designed for the scalability, logistics, and accessibility of TIL therapy. It is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. It is also developing a class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR) platform. ITIL-168 is an autologous TIL therapy that it is initially developed for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. Its pipeline also includes ITIL-306, its CoStAR-TIL product candidate.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Instil Bio Inc revenues decreased from $138K to $0K. Net loss increased from $37.7M to $156.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase from $19M to $94.3M (expense), General and administrative - Balancing increase from $13.1M to $35M (expense).

Industry: Biotechnology & Medical Research (NEC)

3963 Maple Avenue
Suite 350
DALLAS
TEXAS 75219
US

Income statement

People Also Watch

Bitcoin to US Dollar

21,307.00 Price
-8.620% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 21:00 (UTC)
Spread 60.00

Still looking for a broker you can trust?

Join the 427.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading